Skip to main content
. Author manuscript; available in PMC: 2012 Aug 27.
Published in final edited form as: Cancer Gene Ther. 2009 May 15;16(12):883–891. doi: 10.1038/cgt.2009.33

Figure 5. Conditional DC.RheoIL12 therapy promotes strong peripheral activation of anti-B16 CD8+ T cells if activating ligand is provided within 24h of DC injection and results in durable, specific protection against B16 melanoma rechallenge.

Figure 5

In panel A., spleens were harvested and pooled from 3 animals per cohort on day 25 after mice had received the indicated i.t. therapy. Purified CD8+ T cells were then stimulated in vitro with irradiated B16 (relevant) vs. EL4 (irrelevant) tumor cells, as outlined in Materials and Methods, and levels of mIFN-γ secretion quantitated by specific ELISA. Data are reported as the mean ± SD of triplicate determinations and are representative of 2 independent experiments performed. In panel B., all mice (n=5) rendered tumor-free after treatment with i.t. DC.RheoIL12 and the d1-d5 regimen of ligand were re-challenged on day 45 (post-initial tumor injection) with 105 B16 melanoma vs. 105 MC38 colon carcinoma cells (placed on contralateral flanks) and tumor sizes (mean mm2 ± SD) measured every 3–4 days.